Skip to main content

Table 3 Ex vivo distribution of 18F-FMCH

From: Type 2 diabetes enhances arterial uptake of choline in atherosclerotic mice: an imaging study with positron emission tomography tracer 18F-fluoromethylcholine

 

LDLR−/−ApoB100/100

IGF-II/LDLR−/−ApoB100/100

C57BL/6N

Aorta

1.5 ± 0.11

2.0 ± 0.17a, b

1.2 ± 0.094

Blood

0.98 ± 0.076

0.58 ± 0.066b

0.84 ± 0.090

Intestine

8.1 ± 0.75

11 ± 2.0

8.7 ± 2.9

Kidney

49 ± 2.8

41 ± 5.1

37 ± 3.2

Liver

19 ± 2.8

13 ± 2.0

18 ± 2.9

Lungs

11 ± 0.48

13 ± 1.0a

9.2 ± 0.77

Muscle

0.91 ± 0.086

1.2 ± 0.10

0.86 ± 0.12

Myocardium

6.8 ± 0.44

8.4 ± 0.80

6.3 ± 0.64

Pancreas

7.7 ± 0.78

8.1 ± 0.86

6.0 ± 0.42

Spleen

6.6 ± 0.30

6.7 ± 0.77

5.0 ± 0.61

Urine

20 ± 5.4

6.3 ± 2.1

15 ± 4.0

White adipose tissue

0.50 ± 0.12

0.51 ± 0.12

0.29 ± 0.040

  1. The distribution of 18F-FMCH is measured at 20 min post-injection in non-diabetic (LDLR−/−ApoB100/100) and diabetic (IGF-II/LDLR−/−ApoB100/100) atherosclerotic mice and in healthy (C57BL/6N) controls. The results are expressed as percentage of injected radioactivity dose per gram of tissue (mean ± SEM)
  2. aa significant difference as compared with C57BL/6N mice
  3. ba significant difference as compared with LDLR−/−ApoB100/100 mice